


10/533799
JC17 Rec'd PCT/PTO 04 MAY 2005

In the Claims

Please amend the claims according to the claim listing provided below.

1. (currently amended) A compound of Formula (I):



wherein:

R₁ is C₁₋₈ alkyl, C₃₋₆ cycloalkyl or C₁₋₆ haloalkyl, wherein the C₁₋₈ alkyl, C₃₋₆ cycloalkyl and C₁₋₆ haloalkyl groups are optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, aryl, substituted aryl, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, heteroaryl, heterocyclyl, hydroxyl, nitro and thiol;

R₂, R₃ and R₄ are each independently selected from the group consisting of H, C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, hydroxyl, nitro and thiol; and

R₅ is H or C₁₋₆ alkyl; or

a pharmaceutically acceptable salt, solvate or hydrate ~~or a solvate thereof~~;
provided that:

a) when R₅ is ethyl, and R₂, R₃ and R₄ are H then R₁ is not methyl or triphenylmethyl;

b) when R₅ is n-pentyl, and R₂, R₃ and R₄ are H then R₁ is not n-butyl;

c) when R₅ is methyl, and R₂, R₃ and R₄ are H then R₁ is not pyrrolidin-1-ylmethyl, 3-tert-butyl-2-hydroxy-5-methyl-benzyl, methyl, or dimethylaminomethyl;

d) when R₅ is methyl, R₂ is carbomethoxy and R₃ and R₄ are both H then R₁ is not methyl;

e) when R₂, R₃, R₄ and R₅ are all H then R₁ is not 2-amino-2-carboxy-ethyl, pyrrolidin-1-ylmethyl, isopropyl, methyl, benzyl, n-butyl, or carboxymethyl; and

f) when R₂, R₄, and R₅ are all H and R₃ is methoxy then R₁ is not methyl.

2. (currently amended) A compound according to claim 1 wherein:

R₁ is C₃₋₆ cycloalkyl or C₁₋₆ haloalkyl, wherein each C₃₋₆ cycloalkyl ~~or~~ and C₁₋₆ haloalkyl group is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, hydroxyl, nitro and thiol;

R₂, R₃ and R₄ are each independently selected from the group consisting of H, C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, hydroxyl, nitro ~~or~~ and thiol; and

R₅ is H or C₁₋₆ alkyl; or

a pharmaceutically acceptable salt, solvate or hydrate ~~or a solvate thereof~~.


3. (currently amended) The compound according to claim 1 ~~or 2~~ wherein R₅ is C₁₋₆ alkyl.
4. (currently amended) The compound according to claim 1 ~~or 2~~ wherein R₅ is H.
5. (currently amended) The compound according to ~~any one of claims 1 to 4~~ wherein R₂, R₃ and R₄ are each independently H or halogen.

6. (currently amended) The compound according to ~~any one of claims 1 to 4~~ wherein R₂, R₃ and R₄ are each independently H or F.
7. (currently amended) The compound according to ~~any one of claims 1 and 3 to 6~~ wherein R₁ is C₁₋₈ alkyl optionally substituted with substituents selected from the group consisting of C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, aryl, substituted aryl, C₃₋₆ cycloalkyl, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, heteroaryl, heterocyclyl, and hydroxyl.
8. (currently amended) The compound according to ~~any one of claims 1 and 3 to 6~~ wherein R₁ is selected from the group consisting of 2-butyl, 3-pentyl, 1-propyl, t-butyl, 1-butyl, 4-Methyl-pentyl, 3-methyl-butyl, 1,3-dimethyl-butyl, 3,3-dimethyl-butyl, 1-heptyl, ethyl, 2,2-dimethyl-propyl, and 1-pentyl.
9. (currently amended) The compound according to ~~any one of claims 1 and 3 to 6~~ wherein R₁ is selected from the group consisting of 3-methoxy-benzyl, 4-methoxy-benzyl, 4-methoxy-phenyl ethyl, 3-methoxy-phenyl ethyl, 3,5-difluorobenzyl, and benzhydryl.
10. (currently amended) The compound according to ~~any one of claims 1 and 3 to 6~~ wherein R₁ is selected from the group consisting of 3-isopropoxypropyl, tetrahydro-furan-2-ylmethyl, 2-methoxy-ethyl, 2-ethylsulfanyl-ethyl, 3-hydroxy-propyl, allyl, cyclopropylmethyl, but-2-ynyl, 2-methoxy-1-methyl-ethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2-ethoxy-ethyl, and 1,2-dimethyl-propyl.
11. (currently amended) The compound according to ~~any one of claims 1 to 6~~ wherein R₁ is selected from the group consisting of cyclopentyl, cyclohexyl, cyclopropyl, and cyclobutyl.
12. (currently amended) The compound according to claim 1 selected from the group consisting of:
 - 1-Cyclopentyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(2'-Butyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(3'-Pentyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-Cyclohexyl-1H-benzotriazole-5-carboxylic acid

1-Propyl-1H-benzotriazole-5-carboxylic acid;
1-Cyclopropyl-1H-benzotriazole-5-carboxylic acid;
1-(3'-Isopropoxy-propyl)-1H-benzotriazole-5-carboxylic acid;
1-(Tetrahydro-furan-2'-ylmethyl)-1H-benzotriazole-5-carboxylic acid;
1-Cyclobutyl-1H-benzotriazole-5-carboxylic acid;
1-(2-Methoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-(3'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;
1-(4'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;
1-[2'-(4''-Methoxy-phenyl)-ethylamine]-1H-benzotriazole-5-carboxylic acid;
1-[2'-(3''-Methoxy-phenyl)-ethylamine]-1H-benzotriazole-5-carboxylic acid;
1-(3',5'-Difluorobenzyl)-1H-benzotriazole-5-carboxylic acid;
1-(2-Ethylsulfanyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-t-Butyl-1H-benzotriazole-5-carboxylic acid;
1-(3'-Hydroxy-propyl)-1H-benzotriazole-5-carboxylic acid;
1-(1',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;
1-(3',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;
1-Heptyl-1H-benzotriazole-5-carboxylic acid;
1-(2'-Methoxy-1'-methyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-(2'-Hydroxy-1'-hydroxymethyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-Ethyl-1H-benzotriazole-5-carboxylic acid;
1-Pentyl-1H-benzotriazole-5-carboxylic acid;
1-(2',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;
1-(2'-Ethoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-(1',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;
1-Benzhydryl-1H-benzotriazole-5-carboxylic acid;
1-Allyl-1H-benzotriazole-5-carboxylic acid;
1-Butyl-1H-benzotriazole-5-carboxylic acid;
1-(Cyclopropylmethyl)-1H-benzotriazole-5-carboxylic acid;
1-(But-2-ynyl)-1H-benzotriazole-5-carboxylic acid;
1-(4'-Methyl-pentyl)-1H-benzotriazole-5-carboxylic acid; and
1-(3'-Methyl-butyl)-1H-benzotriazole-5-carboxylic acid; or
a pharmaceutically acceptable salt, solvate or hydrate thereof.

13. (currently amended) A pharmaceutical composition comprising a compound according to:

a) Formula (I):



wherein:

R₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl or C₁₋₆ haloalkyl, wherein each C₁₋₆ alkyl, C₃₋₆ cycloalkyl ~~or~~ and C₁₋₆ haloalkyl group is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, hydroxyl, nitro ~~or~~ and thiol;

R₂, R₃ and R₄ are each independently selected from the group consisting of H, C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, hydroxyl, nitro ~~or~~ and thiol; and

R₅ is H or C₁₋₆ alkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof; ~~or~~

~~b) any one of claims 1 to 12; wherein said compound is,~~ in combination with a pharmaceutically acceptable carrier.

14. (original) A pharmaceutical composition according to claim 13 further comprising an agent selected from the group consisting of α -glucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione.

15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. (currently amended) A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically effective amount of a ~~compound~~ pharmaceutical composition according to claim 13 ~~any one of claims 1 to 12.~~
21. (original) A method according to claim 20 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
22. (canceled)
23. (canceled)
24. (canceled)
25. (canceled)
26. (new) A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound according to claim 1.

27. (new) A method according to claim 26 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
28. (new) The pharmaceutical composition according to claim 13 wherein said compound is selected from the group consisting of:
- 1-Isopropyl-1H-benzotriazole-5-carboxylic acid;
 - 1-Cyclopentyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(2'-Butyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(3'-Pentyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-Cyclohexyl-1H-benzotriazole-5-carboxylic acid;
 - 1-Benzyl-1H-benzotriazole-5-carboxylic acid;
 - 1-Propyl-1H-benzotriazole-5-carboxylic acid;
 - 1-Cyclopropyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(3'-Isopropoxy-propyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(Tetrahydro-furan-2'-ylmethyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-Cyclobutyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(2-Methoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(3'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(4'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-[2'-(4''-Methoxy-phenyl)-ethyl]-1H-benzotriazole-5-carboxylic acid;
 - 1-[2'-(3''-Methoxy-phenyl)-ethyl]-1H-benzotriazole-5-carboxylic acid;
 - 1-(3',5'-Difluorobenzyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(2-Ethylsulfanyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-t-Butyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(3'-Hydroxy-propyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(1',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(3',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-Heptyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(2'-Methoxy-1'-methyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(2'-Hydroxy-1'-hydroxymethyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-Ethyl-1H-benzotriazole-5-carboxylic acid;
 - 1-Pentyl-1H-benzotriazole-5-carboxylic acid;

1-(2',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;
1-(2'-Ethoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-(1',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;
1-Benzhydryl-1H-benzotriazole-5-carboxylic acid;
1-Allyl-1H-benzotriazole-5-carboxylic acid;
1-Butyl-1H-benzotriazole-5-carboxylic acid;
1-(Cyclopropylmethyl)-1H-benzotriazole-5-carboxylic acid;
1-(But-2-ynyl)-1H-benzotriazole-5-carboxylic acid;
1-(4'-Methyl-pentyl)-1H-benzotriazole-5-carboxylic acid; and
1-(3'-Methyl-butyl)-1H-benzotriazole-5-carboxylic acid; or
a pharmaceutically acceptable salt, solvate or hydrate thereof.